Pharmacyclics I Janssen- COMMERCIAL
WARNINGS AND PRECAUTIONS
Hemorrhage, infections, cytopenias, cardiac arrhythmias, hypertension, second primary malignancies, tumor lysis syndrome, and embryo-fetal toxicity.
ADVERSE REACTIONS
The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%).
*Treatment-emergent decreases (all grades) were based on laboratory measurements.
Please see complete Important Safety Information in the video below.
1L=frontline, CLL=chronic lymphocytic leukemia, FCR=fludarabine, cyclophosphamide, and rituximab, SLL=small lymphocytic lymphoma, WM=Waldenström''s macroglobulinemia